In the 2021 San Antonio Breast Cancer Conference (SABCS), a report from the Memorial Sloan Kettering Cancer Center showed that the median PFS of first-line CDK4/6 inhibitor combined with endocrine treatment for gBRCA2-mutated metastatic BC was shorter than that for gBRCA2 wild type BC (7.0 months vs 14.7 months; HR = 2.32, 95% CI  1.38–3.91, P < 0.05). The gene discussed is CDK4; the disease is breast cancer.